Clinical Trial VICCMD1403
An Open Label, Phase II Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification
- Protocol No. VICCMD1403
- Open Date: 06/02/2014
- Staging: Phase II
- Age Group: Adults
- Scope: National
- Objective: The primary objective of this study is to determine the objective response rate at 8 weeks (ORR8) for all cohorts
- Disease Sites: Urologic; Neuro-Oncology; Bladder; Ovarian; Esophageal; Colon; Uterine; Gastric/Gastroesophageal
- Therapies: Chemotherapy - cytotoxic; Hormonal Therapy; Molecular Targeted Agents / Immunotherapy / Biologics
- Drugs: Fulvestrant; Herceptin; Neratinib (HKI-272); Paclitaxel; Trastuzumab (Herceptin)
- Participating Institutions: Vanderbilt University
- National Clinical Trial ID: NCT01953926
- Secondary Protocol No: PUMA-NER-5201
|Ages Eligible for Study:||18 Years and older|
|Genders Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
• Histologically confirmed cancers for which no curative therapy exists.
• Documented HER2 mutation.
• Prior treatment with any pan-HER TKI (eg, lapatinib, afatinib, dacomitinib, neratinib).
• Patients who are receiving any other anticancer agents.
• Symptomatic or unstable brain metastases.
• Women who are pregnant or breast-feeding.
Note: There are additional inclusion and exclusion criteria. The study center will determine if you meet all of the criteria.